80 likes | 92 Views
u201cCoherent Market Insights u201cINDIA IMMUNE-ONCOLOGY DRUGS MARKET u2013 GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027u2033
E N D
INDIA IMMUNE-ONCOLOGY DRUGS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION India Immune-Oncology Drugs Market - Overview India Immune-Oncology Drugs Market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others) was valued at US$ 172.8 million in 2018 and is projected to exhibit a CAGR of 13.1% over the forecast period (2018 - 2026). Increasing cancer research, new product launches, sales and marketing approvals, and rising number of development programs are major factors expected to drive growth of the India immune-oncology drugs market. Various organizations are focused on launching new products to aid India immune-oncology drugs market to gain fair share in the market. For instance, in July 2018, Dr. Reddy’s Laboratories Ltd. launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India. It is indicated for the treatment of HER2-positive cancer (early breast cancer, metastatic breast cancer, and metastatic gastric cancer). Moreover, in November 2017, Biocon launched Krabeva, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian, and brain cancers, in India. Furthermore, some companies are engaged in receiving sales and marketing approvals from regulatory bodies of India to import their products, which can further increase India immune- oncology drugs market size. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/india- immune-oncology-drugs-market-2631 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION For instance, in September 2016, Dr. Reddy’s Laboratories Ltd., expanded its strategic collaboration with Amgen to market and distribute Amgen’s three drugs (XGEVA ( denosumab), Vectibix (panitumuma), and Prolia (denosumab)), in India for the treatment of oncology and osteoporosis. Bristol-Myers Squibb emphasizes on collaborations with other biopharmaceutical and pharmaceutical companies to advance their own research on novel compounds. For instance, AbbVie and Bristol-Myers Squibb collaborated in 2017, for research on Opdivo and ABBV-399. Bristol-Myers-Squibb and Seattle Genetics collaborated for research on Adcetris (brentuximab) and Opdivo (Nivolumab) for the treatment of relapsed or refractory Hodgkin lymphoma. Browse 38 Market Data Tables and 21 Figures spread through 162 Pages and in-depth TOC on "India immune-oncology drugs market, By Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, and Cancer Vaccines) and By Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others)- Global Forecast to 2026" AstraZeneca Plc is engaged in creating awareness among the Indian community, in order to increase its market share in India. For instance, in February 2018, AstraZeneca Pharma India Limited and Indian Cancer Society launched a nationwide cancer awareness initiative – Cancer Screening for Women. Under this program, free, specialized cancer-screening was conducted across the country for women from underprivileged families. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2631 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Key Takeaways of the India Immune-Oncology Drugs Market: India immune-oncology drugs market is expected to expand at a CAGR of 13.1% during the forecast period (2018–2026), owing to increasing research & development and demand for genomic and repertoire sequencing-based research. Among drug type, Monoclonal Antibodies segment is expected to hold major revenue share in 2026, owing to increasing number of product launches. For instance, in August 2014, India- based generics maker Hetero Group (Hetero) launched its biosimilar ‘Rituximab’ under the brand name MABALL, in India. Rituximab is recommended as the first-line treatment for Non- Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL) and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml. Major players operating in India immune-oncology drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited. For instance, in June 2018, AstraZeneca Pharma India Limited received Import & Market permission for Durvalumab (Imfinzi) in India, by the Drug Controller General of India (DCGI) Manufacturers in India immune-oncology drugs market are focusing on strategic collaboration, in order to gain significant market share. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2631 © Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators Private and Government organization Distributors, Retailors and Value Added Resellers Outsourcing Companies Healthcare IT Solutions Developers Universities and Business Schools. © Coherent market Insights. All Rights Reserved
KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved